For those of you treating cells with DTT for patients taking daratumumab/darzalex: Have you come across a positive autocontrol, with treated and untreated cells?
Currently, patient on DARA: initial screen-panagglutinin, auto-positive.
Testing with treated cells: screen-negative, auto-positive.
QC-valid (testing Kpos and Epos cell) antigen typing for K-neg, E-pos
I have been unable to find any research with this information. We are currently in the process of validating DTT treatment.
Any advice would be welcomed.
We are getting full genotype on our dara patients before they start on the drug. Currently we have one patient that requires transfusion and are giving matched blood. Our question is how often should we send a sample to our reference lab for testing? There doesn't seem to be a whole lot of agreement on what to do. Every 72 hours is unrealistic. Any guidance would be appreciated. Thanks, Karen